Compare
FibroBiologics, Inc. vs MAIA Biotechnology, Inc. vs Cocrystal Pharma, Inc. vs Kala Bio, Inc.
| Latest fiscal year | FibroBiologics, Inc. FBLG | MAIA Biotechnology, Inc. MAIA | Cocrystal Pharma, Inc. COCP | Kala Bio, Inc. KALA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$18.65M | -$22.40M | -$8.83M | -$26.98M |
| EPS (Diluted) | -$0.42 | -$0.70 | -$0.78 | -$3.31 |
| Operating cash flow | -$16.39M | -$18.84M | -$8.19M | -$31.99M |
| Free cash flow | -$16.66M | n/a | -$8.20M | n/a |
| Cash & equivalents | $4.89M | $0 | $7.03M | $7.56M |
| Total assets | $9.62M | $9.70M | $9.71M | $9.49M |
| Total liabilities | $3.46M | $7.33M | $3.38M | $2.49M |
| Shareholders' equity | $6.16M | $2.38M | $6.33M | $7.00M |
| Return on year-end equity | -302.9% | -942.7% | -139.5% | -385.6% |
| Shares outstanding | n/a | 38.62M | 13.78M | 27.85M |
Revenue, most recent five fiscal years
| Fiscal year | FibroBiologics, Inc. | MAIA Biotechnology, Inc. | Cocrystal Pharma, Inc. | Kala Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2024-12-31 | $2.01M Ended 2020-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2023-12-31 | $6.56M Ended 2019-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2022-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $3.89M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $11.24M Ended 2021-12-31 |